During the past 3 years of EUnetHTA’s operations in the framework of the Joint Action 2, an expanded suite of practical approaches and tools for HTA production has been developed and tested through a series of field-testing exercises in EUnetHTA, both in the framework of joint assessments and by individual European HTA organisations in their local HTA processes. The detailed results of these activities will be included in the final technical report to the European Commission (to be delivered in May 2016).
The last meeting of EMA-EUnetHTA in the framework of the EUnetHTA JA2 activities took place on November 23, 2015 and hosted by the Danish Health Authority in Copenhagen, Denmark.
EUnetHTA JA2 delivers an upgraded universal HTA Core Model for flexible application across health technologies. The updated HTA Core Model Licence and Guiding Principles on Use clarify conditions for its use by anyone
We are happy to announce that the final guideline on "Therapeutic medical devices" is now available.
We are pleased to announce that the Joint "Rapid relative effectiveness assessment of new pharmaceuticals for the treatment of chronic Hepatitis C" og WP5-SA6 is now available.